Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Equity (2017 - 2025)

Rein Therapeutics (RNTX) has disclosed Return on Equity for 9 consecutive years, with 0.34% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 53.0% to 0.34% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.34% through Dec 2025, up 53.0% year-over-year, with the annual reading at 0.28% for FY2025, 58.0% up from the prior year.
  • Return on Equity for Q4 2025 was 0.34% at Rein Therapeutics, up from 1.29% in the prior quarter.
  • The five-year high for Return on Equity was 0.19% in Q1 2024, with the low at 1.46% in Q1 2023.
  • Average Return on Equity over 5 years is 0.8%, with a median of 0.78% recorded in 2024.
  • The sharpest move saw Return on Equity skyrocketed 169bps in 2021, then plummeted -103bps in 2025.
  • Over 5 years, Return on Equity stood at 0.56% in 2021, then tumbled by -135bps to 1.33% in 2022, then surged by 78bps to 0.29% in 2023, then plummeted by -199bps to 0.87% in 2024, then soared by 61bps to 0.34% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.34%, 1.29%, and 1.25% for Q4 2025, Q3 2025, and Q2 2025 respectively.